Abbott Laboratories  

(Public, NYSE:ABT)   Watch this stock  
Find more results for ABT
43.81
+0.03 (0.07%)
Nov 21 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 43.71 - 44.19
52 week 35.65 - 44.77
Open 44.15
Vol / Avg. 6.50M/5.12M
Mkt cap 65.97B
P/E 40.13
Div/yield 0.22/2.01
EPS 1.09
Shares 1.51B
Beta 0.39
Inst. own 69%
Jan 20, 2015
Q4 2014 Abbott Laboratories Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 11, 2014
Abbott Laboratories at Credit Suisse Healthcare Conference
Oct 22, 2014
Q3 2014 Abbott Laboratories Earnings Release
Oct 22, 2014
Q3 2014 Abbott Laboratories Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 8.62% 10.91%
Operating margin 14.32% 12.03%
EBITD margin - 20.49%
Return on average assets 4.20% 4.33%
Return on average equity 7.59% 9.18%
Employees 69,000 -
CDP Score - 84 B

Address

C/O TAX DEPT D367 & AP6D 100 Abbott Park Road
ABBOTT PARK, IL 60064-3500
United States - Map
+1-847-9376100 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia

Description

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture, and sale of a portfolio of science-based health care products. Abbott operates in four business segments: diagnostics, medical devices, nutritionals and generic pharmaceuticals. Geographically, 30% of its revenue is generated in the United States; 30% in Western Europe, Canada, Japan and Australia, and 40% in the economies, including India, China, Russia and Brazil. In January 2013, the Company completed the separation of its research-based pharmaceuticals business, which became AbbVie, a new independent biopharmaceutical company. In August 2013, Abbott Laboratories completed its acquisition of OptiMedica Corporation. In August 2013, Abbott Laboratories completed its acquisition of IDEV Technologies.

Officers and directors

Miles D. White Chairman of the Board, Chief Executive Officer
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Thomas C. Freyman Chief Financial Officer, Executive Vice President - Finance
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Hubert L. Allen Executive Vice President, General Counsel, Secretary
Age: 48
Bio & Compensation  - Reuters
Stephen R. Fussell Executive Vice President - Human Resources
Age: 56
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Richard W. Ashley Executive Vice President - Corporate Development
Age: 70
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Brian J. Blaser Executive Vice President - Diagnostics Products
Age: 49
Bio & Compensation  - Reuters
John M. Capek Ph.D. Executive Vice President - Medical Devices
Age: 52
Bio & Compensation  - Reuters
Michael J. Warmuth Executive Vice President - Established Pharmaceuticals
Age: 51
Bio & Compensation  - Reuters
Jaime Contreras Senior Vice President - Core Laboratory Diagnostics, Commercial Operations
Age: 57
Bio & Compensation  - Reuters
Georges H. De Vos Senior Vice President - Established Pharmaceuticals, Emerging Markets
Age: 55
Bio & Compensation  - Reuters